Name: Our Journey Beyond Sunset Boulevard: Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on "True" Long-Te (en Inglés)
Price: 130.48 USD
Availability: InStock
Author: Gordon, Erlinda M. ; Hall, Frederick
ISBN: 9781839694158

portada Our Journey Beyond Sunset Boulevard: Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on "True" Long-Te (en Inglés)

Formato

Libro Físico

Autor

Frederick Hall

Erlinda M. Gordon

Editorial

Intechopen

Idioma

Inglés

N° páginas

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 0.6 cm

Peso

0.30 kg.

ISBN13

9781839694158

Categorías

Oncología
Especialidades de enfermería

Our Journey Beyond Sunset Boulevard: Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on "True" Long-Te (en Inglés)

Frederick Hall (Autor) · Erlinda M. Gordon (Autor) · Intechopen · Tapa Dura

Libro Nuevo

$ 130.48

$ 260.95

Ahorras: $ 130.48

50% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 05 de Agosto y el Lunes 19 de Agosto.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Our Journey Beyond Sunset Boulevard: Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on "True" Long-Te (en Inglés)"

The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided "silver bullet" (dnG1 killer gene) to the cancer clinic with "Expanded Access" in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of "informed consent," this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors-validating "pathotropic" (disease-seeking) tumor targeting avant la lettre.